Preclinical Evaluation of DT2216
- Selective and prolonged tumor tissue accumulation of DT2216 is important for its improved antitumor activity and reduced platelet toxicity
- DT2216 exhibits a durable anti-leukemia/tumor effect in various preclinical xenograft models
- This effect is likely attributable to its effect not only on tumor cells but also on various stromal cells in tumor microenvironment, including therapy-induced senescent cells and tumorinfiltrating regulator T cells